Other Immunomodulatory Treatment for Cytokine Storm Syndromes

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2024 Aug 8

PMID 39117842

Authors

Ezgi Deniz Batu

Seza Ozen

Affiliations

Soon will be listed here.

Abstract

Cytokine storm syndromes (CSS) include different entities such as macrophage activation syndrome, primary and secondary hemophagocytic lymphohistiocytosis (HLH), and multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. An effective management strategy is critical in CSS. While biologics have become an essential part of CSS treatment, hematopoietic stem cell transplantation (HSCT) has changed the fate of primary HLH patients. This chapter will focus on the available alternative immunomodulatory therapies in CSS, which include corticosteroids, cyclosporine A, intravenous immunoglobulin, interleukin 18 binding protein, therapeutic plasmapheresis, HSCT, and mesenchymal stromal cell-based therapies.

References

Tothova Z, Berliner N . Hemophagocytic Syndrome and Critical Illness: New Insights into Diagnosis and Management. J Intensive Care Med. 2014; 30(7):401-12. PMC: 4099298. DOI: 10.1177/0885066613517076. View

Batu E . Glucocorticoid treatment in juvenile idiopathic arthritis. Rheumatol Int. 2018; 39(1):13-27. DOI: 10.1007/s00296-018-4168-0. View

Henter J, Horne A, Arico M, Egeler R, Filipovich A, Imashuku S . HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2006; 48(2):124-31. DOI: 10.1002/pbc.21039. View

Boom V, Anton J, Lahdenne P, Quartier P, Ravelli A, Wulffraat N . Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2015; 13:55. PMC: 4669611. DOI: 10.1186/s12969-015-0055-3. View

Quartier P . Systemic Juvenile Idiopathic Arthritis/Pediatric Still's Disease, a Syndrome but Several Clinical Forms: Recent Therapeutic Approaches. J Clin Med. 2022; 11(5). PMC: 8911482. DOI: 10.3390/jcm11051357. View

Onel K, Horton D, Lovell D, Shenoi S, Cuello C, Angeles-Han S . 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2022; 74(4):521-537. PMC: 10124899. DOI: 10.1002/acr.24853. View

Villacis-Nunez D, Jones K, Jabbar A, Fan L, Moore W, Peter A . Short-term Outcomes of Corticosteroid Monotherapy in Multisystem Inflammatory Syndrome in Children. JAMA Pediatr. 2022; 176(6):576-584. PMC: 8961405. DOI: 10.1001/jamapediatrics.2022.0292. View

Son M, Murray N, Friedman K, Young C, Newhams M, Feldstein L . Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes. N Engl J Med. 2021; 385(1):23-34. PMC: 8220972. DOI: 10.1056/NEJMoa2102605. View

Chighizola C, Ong V, Meroni P . The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review. Clin Rev Allergy Immunol. 2016; 52(3):401-423. DOI: 10.1007/s12016-016-8582-3. View

10.

Fric J, Zelante T, Wong A, Mertes A, Yu H, Ricciardi-Castagnoli P . NFAT control of innate immunity. Blood. 2012; 120(7):1380-9. DOI: 10.1182/blood-2012-02-404475. View

11.

Liddicoat A, Lavelle E . Modulation of innate immunity by cyclosporine A. Biochem Pharmacol. 2019; 163:472-480. DOI: 10.1016/j.bcp.2019.03.022. View

12.

Zanoni I, Granucci F . Regulation and dysregulation of innate immunity by NFAT signaling downstream of pattern recognition receptors (PRRs). Eur J Immunol. 2012; 42(8):1924-31. DOI: 10.1002/eji.201242580. View

13.

Bagri N, Gupta L, Sen E, Ramanan A . Macrophage Activation Syndrome in Children: Diagnosis and Management. Indian Pediatr. 2021; 58(12):1155-1161. PMC: 8732159. View

14.

Schulert G, Grom A . Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2014; 66:145-59. PMC: 5846123. DOI: 10.1146/annurev-med-061813-012806. View

15.

Bergsten E, Horne A, Arico M, Astigarraga I, Egeler R, Filipovich A . Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017; 130(25):2728-2738. PMC: 5785801. DOI: 10.1182/blood-2017-06-788349. View

16.

Mouy R, Stephan J, Pillet P, Haddad E, Hubert P, Prieur A . Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996; 129(5):750-4. DOI: 10.1016/s0022-3476(96)70160-9. View

17.

Ravelli A, Viola S, De Benedetti F, Magni-Manzoni S, Tzialla C, Martini A . Dramatic efficacy of cyclosporine A in macrophage activation syndrome. Clin Exp Rheumatol. 2001; 19(1):108. View

18.

Hiraoka T, Tsuge M, Kondo Y . Cyclosporine for the treatment of multisystem inflammatory syndrome in children with coronary artery aneurysms. BMJ Case Rep. 2022; 15(6). PMC: 9185400. DOI: 10.1136/bcr-2022-250375. View

19.

Suzuki T, Suenaga T, Sakai A, Sugiyama M, Mizokami M, Mizukami A . Case Report: Ciclosporin A for Refractory Multisystem Inflammatory Syndrome in Children. Front Pediatr. 2022; 10:890755. PMC: 9194446. DOI: 10.3389/fped.2022.890755. View

20.

Thompson P, Allen C, Horton T, Jones J, Vinks A, McClain K . Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009; 52(5):621-5. PMC: 3660724. DOI: 10.1002/pbc.21838. View